



X

RECEIVED

Feb 1751

JUL 11 2002

PATENT

TECH CENTER 1600/2000  
TRADEMARK OFFICE

Attorney Docket No.: 4318.224-US

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box DD  
Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD  
Commissioner for Patents  
Washington, DC 20231

on February 6, 2002.

Julie Tabarovsky  
(name of person mailing paper)

J. Tabarovsky  
(signature of person mailing paper)

RECEIVED  
MAR 11 2002  
TC 1700

Copy of References  
Original Document

RECEIVED  
FEB 28 2002  
TC 1700



Attorney Docket No.: 4318.224-US

BEST AVAILABLE COPY

#2  
mb  
5/15/02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Bisgaard-Frantzen et al., J. Appl. Glycosci., Vol. 46, No. 2, pp. 199-205 (1999)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.


The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **b for** the mailing date of a first Office action on the merits, or

COPY OF REFERENCES  
ORIGINALLY FILED  
RECEIVED

RECEIVED  
FEB 28 2002  
TC 1700  
RECEIVED  
MAR 11 2002  
TC 1700

**BEST AVAILABLE COPY**

b for the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.



Date: February 6, 2002

Respectfully submitted,

  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

COPY OF PAPER  
ORIGINALLY FILED

**RECEIVED**

JUL 11 2002

TECH CENTER 1600/2900

**RECEIVED**  
FEB 28 2002  
**TC 1700**

**RECEIVED**  
MAR 11 2002  
**TC 1700**